Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ohara Launches Class I Recall for Nizatidine over Carcinogen Risks
October 24, 2019
- Takeda Bags Worldwide Rights for Cour's Celiac Disease Treatment
October 24, 2019
- RWD Suggests Lower Serious Adverse Event Risks for Entyvio vs. Anti-TNFα Antibodies: Takeda
October 24, 2019
- Zolgensma’s Japan Launch Delayed into 2020 as Sakigake Review Drags On, MHLW Still Eager to Make Decision by Year-End
October 23, 2019
- Tecentriq plus Avastin Extend OS, PFS in 1st Line HCC
October 23, 2019
- In Shocking U-Turn, Biogen/Eisai Say to File Aducanumab in Early Next Year
October 23, 2019
- Parexel Looks to Set Itself Apart from Rivals through Consulting Services
October 23, 2019
- Sumitomo Dainippon Lifts Q2 Earnings Guidance on Solid Sales in Japan, US, China
October 23, 2019
- European Panel Snubs Daiichi Sankyo’s Quizartinib
October 21, 2019
- JAK Debuts Draw Near in Japan Atopic Dermatitis Market, 1st Likely to Get Listing Next Spring
October 21, 2019
- FDA OKs Xofluza for Flu Patients Carrying High Complication Risks
October 21, 2019
- Shionogi, Janssen, Alzheimer’s Drug Discovery Foundation Join Forces to Develop AD Biomarkers
October 21, 2019
- Kyowa Kirin Recalling Mitomycin over Unauthorized Manufacturing Method, Supply Won’t Resume until 2021
October 18, 2019
- US FDA Panel Backs Shionogi’s Novel Antibiotic
October 18, 2019
- Sumitomo Dainippon Drops Bid to Buy Cynata
October 18, 2019
- FDA Gives Priority Status to Daiichi Sankyo/AZ’s HER2-Tageting ADC
October 18, 2019
- Ranitidine Compensation Programs Draw Complaints from Pharmacists, Separate Billing Seen “Unrealistic”
October 17, 2019
- Xofluza Filed in Japan for Post-Exposure Prophylaxis
October 17, 2019
- Asahi Kasei Initiates Voluntary Recall of Nafamostat after Glass Fragment Found in Vial
October 17, 2019
- Takeda to Divest 30 OTC, Non-Core Assets to Swiss Firm
October 16, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…